Most pharmaceutical companies that invest in AI start with a pilot. A pilot is the right approach: it limits risk, produces evidence before large-scale commitment, and forces clarity about what success looks like. The problem is that roughly 70% of pharma AI pilots stall before reaching enterprise deployment. They produce useful results within their scope, and then nothing happens. The pilot becomes a reference project rather than the foundation for a scaled system.
Understanding the structural difference between a pilot and an enterprise deployment, and designing the pilot with the transition in mind, is what separates AI investments that scale from those that do not.
What a Pharma AI Pilot Is
A pilot is a scoped, time-limited deployment of an AI capability against a specific problem with a defined user group. In pharmaceutical AI, typical pilot scopes include: semantic document search across one product line's formulation records, AI-assisted eTMF review for one trial, or sales rep intelligence for one therapy area in one region.
A well-run pilot has three characteristics. First, a measurable baseline: the time currently spent on the task the AI will address, documented before the pilot begins, so the impact can be quantified. Second, a defined success criteria: what outcome would justify moving to enterprise deployment. Third, a fixed timeline: typically four to eight weeks for the pilot phase, with a clear decision point at the end.
Pilots typically go live within four to six weeks for document search applications. eTMF review pilots and ELN deployments may take six to eight weeks, depending on the complexity of the existing document environment and the integration requirements.
What a Full Enterprise Deployment Adds
An enterprise deployment is not just a bigger pilot. It involves several additional components that do not exist at pilot scale:
- Full corpus coverage: A pilot typically covers one product line, one trial, or one regional team. An enterprise deployment covers the full document library, all trials or programmes, or the entire field force. This involves more complex data ingestion, longer indexing timelines, and more rigorous quality validation of the indexed content.
- System integrations: Enterprise deployments connect AI systems to existing LIMS, DMS, ERP, CRM, and QMS platforms. These integrations are where most implementation time is spent. A pilot can often run standalone. An enterprise deployment cannot.
- Role-based access at scale: A pilot with a small user group can manage access informally. An enterprise deployment requires a formal access control architecture: who can see what, governed by role and programme assignment, enforced by the system rather than by procedure.
- Validation and documentation: For GMP-regulated systems, enterprise deployment requires formal validation: Installation Qualification, Operational Qualification, and Performance Qualification documentation. This is a significant effort that pilots typically defer.
- Change management and training: At enterprise scale, the number of users, the variety of workflows, and the organisational change required are all substantially larger than at pilot scale.
Why Pilots Stall
The most common reasons pharma AI pilots fail to scale are not technical. They are organisational. The pilot was run by a motivated team without executive sponsorship for the enterprise deployment. The budget for the pilot was approved but no path to enterprise funding was established. The pilot produced results but no one documented the ROI case clearly enough to justify the larger investment. The vendor delivered the pilot but lacked the capability to manage a full enterprise rollout.
The pilot is where you prove the technology works. The enterprise deployment is where you build the business case and the organisational commitment in parallel, not after.
How to Structure a Pilot That Scales
Three practices consistently distinguish pilots that lead to enterprise deployment from those that do not.
Involve the enterprise stakeholders from day one. The people who will need to approve enterprise funding and the IT team that will manage the integration should be in the pilot from the start, not brought in after results are available. Their involvement in the pilot is what creates the internal advocacy for the enterprise investment.
Document the ROI from the pilot rigorously. Time saved per user, error rates before and after, reduction in preparation time for specific tasks: these numbers are the enterprise business case. If the pilot does not produce documented, quantified outcomes, the enterprise investment conversation will be difficult regardless of how positive the team's experience was.
Choose a vendor with demonstrated enterprise capability. A vendor that specialises in pilots but has not delivered enterprise-scale pharma AI deployments will struggle with the integration, validation, and change management requirements of a full rollout. Checking reference deployments at enterprise scale before signing a pilot agreement is not premature due diligence.
Start with a Pilot. Build Toward Enterprise.
Livo Assistant runs pharma AI pilots in four to six weeks and has the enterprise deployment track record to take them further. Talk to our team about scoping a pilot for your organisation.
See Pharma Solutions →